Invention Grant
US09328149B2 Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
有权
突变和噬菌体T4纳米颗粒从鼠疫耶尔森氏菌中排列F1-V免疫原作为下一代瘟疫疫苗
- Patent Title: Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
- Patent Title (中): 突变和噬菌体T4纳米颗粒从鼠疫耶尔森氏菌中排列F1-V免疫原作为下一代瘟疫疫苗
-
Application No.: US14320731Application Date: 2014-07-01
-
Publication No.: US09328149B2Publication Date: 2016-05-03
- Inventor: Venigalla B. Rao , Pan Tao
- Applicant: The Catholic University of America
- Applicant Address: US DC Washington
- Assignee: The Catholic University of America
- Current Assignee: The Catholic University of America
- Current Assignee Address: US DC Washington
- Agency: Alchemy-Partners, PC
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K14/24 ; A61K39/02 ; C07K14/005

Abstract:
Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal β-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the β-strand of F1 of Yersinia pestis is duplicated to eliminate polymerization but to retain the T cell epitopes. The mutated F1 is fused to the V antigen of Yersinia pestis to thereby form a fusion protein F1mut-V mutant, which produces a completely soluble monomer. The fusion protein F1mut-V is then arrayed on phage T4 nanoparticles via a small outer capsid protein, Soc, from a T4 phage or a T4-related phage. Both the soluble and T4 decorated F1mut-V provided approximately 100% protection to mice and rats against pneumonic plague evoked by high doses of Yersinia pestis CO92.
Public/Granted literature
Information query